Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  DiaMedica Inc.    DMA   CA25253T1075

DIAMEDICA INC. (DMA)
Mes dernières consult.
Most popular
  Report  
SummaryNewsCalendarCompany 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

DiaMedica : Issues Stock Option Grant

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/20/2017 | 12:31am CEST

MINNEAPOLIS, June 19, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA) (OTCQB:DMCAF), today announces that the Board of Directors has granted options to purchase 1,775,000 common shares of the Corporation to the Company's management and board of directors at an exercise price of $0.32 per share. These options were awarded in accordance with the Company's stock option plan for a ten-year term.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica's shares are listed on the TSX Venture Exchange under the trading symbol "DMA" and on the OTCQB under the trading symbol "DMCAF". For more information, please visit www.diamedica.com. Follow us on social media – Twitter, LinkedIn

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the DiaMedica's filings with the Canadian securities regulators, all of which are available on SEDAR (www.sedar.com). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.

Contact:

Paul Papi
Vice President of Business Development
DiaMedica Therapeutics Inc.
Phone: (617) 899-5941
[email protected]

Source: DiaMedica

2017 GlobeNewswire, Inc., source Press Releases - Canada

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DIAMEDICA INC.
05/03DiaMedica Announces Positive Results From FDA Meeting on Planned Clinical Tri..
GL
04/23DIAMEDICA : Issues Stock Option Grants
AQ
04/18DIAMEDICA : Issues Stock Option Grants
AQ
04/09DIAMEDICA : Therapeutics Announces Appointment of Scott Kellen as Chief Financia..
AQ
04/06DIAMEDICA : to Present at the MicroCap Conference on April 10th in New York City..
AQ
04/05DIAMEDICA : Therapeutics Announces Appointment of Scott Kellen as Chief Financia..
AQ
04/03DIAMEDICA : Therapeutics Announces Final Closing of Private Placement
AQ
03/30DiaMedica Therapeutics Announces Final Closing of Private Placement
GL
03/20DiaMedica Therapeutics Announces Closing of Private Placement
GL
02/22DiaMedica Announces First Enrollment in its PHASE 2 “REMEDY” TRIA..
GL
More news
News from SeekingAlpha
01/31DiaMedica Therapeutics (DMCAF) - Presents At Noble Financial Capital Markets .. 
2016WEEK IN REVIEW : Cross-Border Investments Rule The News 
Managers
NameTitle
Rick John Pauls President, Chief Executive Officer & Director
Richard Dal Pilnik Chairman
Scott Kellen Chief Financial Officer & Secretary
Todd A. Verdoorn Chief Scientific Officer
Michael R. Giuffre Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DIAMEDICA INC.62
CELLTRION, INC.--.--%29 932
IQVIA HOLDINGS INC4.64%21 220
LONZA GROUP1.41%20 059
NEKTAR THERAPEUTICS42.83%14 179
INCYTE CORPORATION-29.71%14 111